{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreic6wzqzevfnv3pp4iigsksfnclhmqjs2adh6v36ghpf2m3bng62cy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mko3oy4biy42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreib2mouldra4hpgwhbovtpf7h7aex2z7rvmq3zcbs42eatqmbi2jdq"
    },
    "mimeType": "image/jpeg",
    "size": 95199
  },
  "path": "/news/2026-04-dual-drug-immunotherapy-resistance-pancreatic.html",
  "publishedAt": "2026-04-29T17:10:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%. There are only two treatment regimens available with limited efficacy. Pancreatic cancers do not respond to immunotherapy where the body's immune system attacks tumor cells.",
  "title": "New dual-target drug may help overcome immunotherapy resistance in pancreatic cancer"
}